In medical devices today, consolidation tends to happen for two reasons. In mature product segments, successful companies consolidate from a position of strength to maintain their market dominance. In nascent segments, lesser players often merge in order to gain the resources to withstand high R&D costs and the expense of building market share. Generally, one type of deal precedes the other, but lately, the ventricular assist device (VAD) market has seen both kinds of deals at once, evidencing the rapid evolution of the market, and pointing out just how little time small players have to achieve critical mass.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?